Liquidia Corporation

Liquidia Corporation is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for patients with serious and unmet medical needs, primarily focusing on pulmonary hypertension. The company's core strategy revolves around its proprietary PRINT® (Particle engineering, REplication, and INkjet printing) technology, which enables the precise manufacturing of complex drug particles. This technology underpins its lead product candidate, YUTREPIA™, an inhaled dry powder formulation of treprostinil, designed for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Liquidia also offers Remodulin®, a treprostinil product administered via continuous intravenous and subcutaneous infusion, and is advancing L606, an investigational liposomal formulation of treprostinil, also targeting PAH and PH-ILD. Through strategic collaborations, such as its license agreement with Pharmosa Biopharm Inc. for L606, Liquidia aims to expand its pipeline and reach a broader patient population. The company's focus on inhaled and sustained-release formulations aims to provide improved patient convenience and potentially enhanced therapeutic profiles compared to existing treatments in the challenging pulmonary hypertension market.